Montelukast, a drug used for the treatment of asthma, is under review by the Medicines and Healthcare products Regulatory Agency (MHRA), following an increased number of Yellow Card reports from patients who have experienced suspected neuropsychiatric adverse reactions, including suicidal behaviour. The drug is an oral leukotriene receptor antagonist, indicated as add-on therapy for treatment … Continue reading MHRA reviewing safety of asthma drug as Yellow Card reports increase